Notes on access to knowledge and IPR challenges of the new European Commission Carlos Moedas, Commissioner for Research, Science and Innovation It is generally accepted that copyright constitutes a barrier for EU researchers and weakens their ability…
Access to life saving medicines debate in plenary of European Parliament
European Parliament Strasbourg Plenary Session Subject: Commission statement – Access to life-saving medicines in Europe Date: September 16 2014 Connie Hedegaard, European Commissioner for Climate Action said that the Commission shared the concerns regarding the affordability of new medical…
Joint civil society letter to Juncker over placing pharmaceuticals under industry
Dear Mr. President-elect, We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market…
Question and debate in EP (16-9-2014) on high prices of life-saving medicines
Oral Question posed by French MEP Michelle Rivasi (Greens) Access to medicines has repeatedly made the headlines in many EU countries over the past 3 months (in France, the UK, Spain, Greece, etc.). The reason for that is the price…
Gobal Broadcast Treaty and public interest
Statement to WIPO SCCR 28 on Broadcasting Treaty by TransAtlantic Consumer Dialogue Broadcasting Treaty: Collateral damage to public access Consumers and users around the world do not want new layers of complications, barriers and costs added to…
TRIPS, the European Commission and the European Medicines Agency´s clinical trial transparency policy
Nothing in international intellectual property law constitutes a serious barrier to the publication of clinical trial data for the sake of public health. In his letter to the European Ombudsman dated 22 May 2014, the Director of the European…